Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy (REFRACT): A Randomised Phase II Trial of Investigator Choice Standard Therapy Versus Sequential Novel Therapy Experimental Arms

NCT05848765 is registered in ClinicalTrials.gov with University of Birmingham as lead sponsor.

NCT NCT05848765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05848765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy (REFRACT): A Randomised Phase II Trial of Investigator Choice Standard Therapy Versus Sequential Novel Therapy Experimental Arms
Lead sponsor
University of Birmingham
Phase
Phase 2
Overall status
Recruiting
Start date
September 4, 2023
Completion date
November 30, 2031
Enrollment
284 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

refractory follicular lymphoma, relapsed follicular lymphoma